Restoring Biological Harmony for Patients with Debilitating Disease
We are harnessing the power of microRNA science to develop therapies that normalize biological pathways and counterbalance disease.
Learn More
DEVELOPMENT PROGRAMS
Our pipeline is focused on serious diseases of high unmet need where the latest discoveries in microRNA biology are challenging traditional drug development paradigms and creating opportunities for novel therapeutic approaches.
Recent Press Releases
- miRagen Announces Pricing of $15.0 Million Public Offering of Common Stock and Warrants to Purchase Common Stock
- miRagen Announces Proposed Public Offering of Common Stock and Warrants to Purchase Common Stock
- miRagen Therapeutics Announces Positive Data for Cobomarsen in Adult T-Cell Leukemia/lymphoma Patients With Residual Disease
- miRagen Therapeutics to Present New Cobomarsen Clinical Trial Data for Adult T-Cell Leukemia/Lymphoma at Two Upcoming Conferences
- miRagen Announces Major Changes to Company’s Strategy